- Home
- AKA vs PLRX Comparison
AKA vs PLRX Comparison
Compare AKA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- PLRX
- Stock Information
- Founded
- AKA 2018
- PLRX 2015
- Country
- AKA United States
- PLRX United States
- Employees
- AKA N/A
- PLRX N/A
- Industry
- AKA Catalog/Specialty Distribution
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- PLRX Health Care
- Exchange
- AKA Nasdaq
- PLRX Nasdaq
- Market Cap
- AKA 193.9M
- PLRX 165.5M
- IPO Year
- AKA 2021
- PLRX 2020
- Fundamental
- Price
- AKA $17.89
- PLRX $3.08
- Analyst Decision
- AKA Buy
- PLRX Buy
- Analyst Count
- AKA 4
- PLRX 10
- Target Price
- AKA $25.50
- PLRX $14.86
- AVG Volume (30 Days)
- AKA 14.4K
- PLRX 3.4M
- Earning Date
- AKA 03-06-2025
- PLRX 03-07-2025
- Dividend Yield
- AKA N/A
- PLRX N/A
- EPS Growth
- AKA N/A
- PLRX N/A
- EPS
- AKA N/A
- PLRX N/A
- Revenue
- AKA $564,586,000.00
- PLRX N/A
- Revenue This Year
- AKA $6.25
- PLRX N/A
- Revenue Next Year
- AKA $4.36
- PLRX N/A
- P/E Ratio
- AKA N/A
- PLRX N/A
- Revenue Growth
- AKA 3.31
- PLRX N/A
- 52 Week Low
- AKA $7.22
- PLRX $2.43
- 52 Week High
- AKA $33.73
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- AKA 53.18
- PLRX 22.51
- Support Level
- AKA $16.17
- PLRX $2.92
- Resistance Level
- AKA $17.42
- PLRX $3.16
- Average True Range (ATR)
- AKA 0.86
- PLRX 0.85
- MACD
- AKA 0.19
- PLRX -0.39
- Stochastic Oscillator
- AKA 83.57
- PLRX 6.22
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.